"ESMO 2025: Padcev plus Keytruda promising in first-line advanced HNSCC" was originally created and published by Clinical ...

MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based ...

The pharmaceutical company has also earned approval for Wegovy in treating metabolic dysfunction-associated steatohepatitis ...

Moderna’s mRNA-4359, when used with Keytruda, achieves a 24% overall objective response rate in patients with melanoma, with ...

Partial remissions and complete metabolic responses in PD-1/PD-L1-resistant cancers First-in-class multi-checkpoint inhibitor with robust ...

Johnson & Johnson’s (J&J’s) bispecific Rybrevant (amivantamab) could provide an effective, novel option for patients with ...

BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesionsData support further development of BT-001 in solid tumors ...

Moderna, Inc. remains under pressure in 2025, despite recent next-gen COVID vaccine approval & cancer vaccine trial. Learn ...

Inhibrx Biosciences, Inc. reports strong phase 2 results for ozekibart in chondrosarcoma, with new cancer data and key ...

BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesionsData support further development of BT-001 in solid tumors ...

New findings show Telomir-1 shuts down cellular energy pathways and mitochondrial function in aggressive breast cancer cells, leading to cell death through iron-dependent regulation. MIAMI, FL / ...